Britannia Pharmaceuticals Ltd

The US FDA issued decisions on two new drug applications combining an on-body infusion device and an established drug last week. While the decisions went different ways – Supernus Pharmaceuticals, In

The US FDA’s user fee goal date calendar for October 2022 is slim, with only two novel agents, AstraZeneca PLC ’s immuno-oncologic tremelimumab and Amicus Therapeutics, Inc. ’ Pompe disease combo AT

Friday the 13th proved lucky for Merck & Co., Inc. ’s Keytruda (pembrolizumab), which claimed an approval bringing the immuno-oncologic into the triple negative breast cancer treatment space. The US

Stada has gained a new value added medicine for its branded specialty pharma operations by acquiring Sweden's Lobsor Pharmaceuticals and its therapy for advanced Parkinson’s disease. The German gro